Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
30 July 2020 | Story Igno van Niekerk | Photo Igno van Niekerk
Keabetswe Malebo was recipient to the scholarship by Abbe Levin.

Great stories are often the result of unexpected connections made across time and space. Upon looking back and connecting dots, one is often surprised at how seemingly random events lead to happy endings, which in themselves become beginnings for new stories.

Leaving a legacy

When Ida Manana Siyila left South Africa in the first half of the twentieth century, no one would have known how her legacy would influence a young student at the UFS many years later. While working for the same American family for more than 30 years, she never stopped learning and working to improve herself. Ida, proud of her dual citizenship, never lost contact with her friends and family in Bloemfontein, wishing to return to Bloemfontein in her old age. Her American family made sure that this wish was fulfilled.

For Keabetswe Malebo, the first six months as a student were tough. An energetic young lady with joy in her voice and a passion for learning and making a difference in her community, Keabetswe had been squatting with a friend while studying at the UFS. The friend was running out of money; there was no way Keabetswe could pay her debt, and her friend could not afford the rent. No rent, no accommodation. No accommodation, no further studies.

Changing a life

Abbe Levin was sincerely grateful for what Ida Siyila had done for her family. In 2017, Abbe made a donation to the UFS requesting that it be used as a scholarship for a disadvantaged student in Ida’s name.

When Keabetswe read about the scholarship, she applied. “I felt it was for me, I was so excited and afraid.” Keabetswe’ s belief, commitment, and hard work were rewarded when she was granted the scholarship. “I got the money just in time to buy a laptop, a printer, and a microwave … and of course to pay the rent I owed my friend.”

Since then, Keabetswe has met Abbe Levin online, and they have become friends, communicating, sharing family pictures and stories, ever grateful for the never-ending story of Ida Manana Siyila.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept